Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


‘Business of science’ digest—May 2021

Checkbox graphic


First CAR-T therapy to target BCMA gets FDA nod

The US Food and Drug Administration (FDA) has approved a chimeric antigen receptor (CAR)-T cell immunotherapy for the treatment of multiple myeloma. The first-in-class BCMA-directed CAR-T therapy received the agency’s go-ahead on 26 March.

Nature Biotechnology

US backs waiving patents on COVID vaccines

In a historic move, the US government has announced that it supports waiving patent protections for COVID-19 vaccines, a measure aimed at boosting supplies so that people around the world can get the shots.


Mix-and-match COVID vaccines trigger potent immune response

Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines.


China’s COVID vaccines are going global—but questions remain

The WHO has approved one of China’s COVID-19 vaccines for use worldwide and another is under review. But published trial data remain scarce.



Business of science: tips and tricks for a perfect investor pitch

Seasoned science entrepreneurs tell Adam Levy how to take the daunting first steps to commercializing your research.

Nature Careers

Business of science: How to register a patent

Scientist-turned-lawyer Tamsen Valoir outlines a key step on the road to commercializing your research.

Nature Careers


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links